Work

Romosuzumab used to treat a 29-year-old patient with anorexia nervosa related osteoporosis – A case report

Year: 2024

Type: article

Abstract: Osteoporosis and decreased bone density is a frequent complication of anorexia nervosa (AN). As of yet, there have been no studies of accomplished treatment of AN-related osteoporosis with romosuzumab, a monoclonal antibody to sclerostin. We report the first case of a premenopausal, 29-year old patient in Switzerland with decreased bone density and osteoporotic fractures due to anorexia nervosa, who completed the treatment with romosuzumab. There was a significant increase in bone mineral density (BMD) after 12 months of therapy. No serious side effects were reported. To date, only bisphosphonates, denosumab and teriparatide have been evaluated in treatment of AN-related osteoporosis in adolescents and premenopausal individuals respectively. Our report demonstrates that romosuzumab might be an alternative treatment option in patients with anorexia nervosa who are at high risk for osteoporotic fractures. To assess the efficacy and safety of romosuzumab in individuals with AN further studies are needed. • Romosuzumab demonstrates a significant osteoanabolic effect and increases bone mineral density in young anorexia nervosa patients significantly • Treatment with romosozumab showed superior clinical efficacy to bisphosphonates and teriparatide in terms of BMD of the lumbar spine, femoral neck and total hip • Romosuzumab treatment for 12 months was well tolerated

Source: Bone Reports

DOI: 10.1016/j.bonr.2024.101803

Authors: Pashija Demolli, Diana Frey

Institution: University Hospital Zurich

Language: English

Topic: Bone health and osteoporosis research

Subfield: Orthopedics and Sports Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,400